Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

• Status: Completed
• Trial end date: 1999-02-01
• Target enrollment: 0
• Participant gender: All

Summary

OBJECTIVES:

I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Research Resources (NCRR)
• Collaborator: University of Tennessee
• Treatments: Mexiletine

Criteria

Patients with painful diabetic neuropathy